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Temozolomide (TMZ), a DNA alkylating agent used in the treatment of melanoma, is believed to mediate its effect by addition of a
methyl group to the O
6 position of guanine in DNA. Resistance to the agent may be in part due to the activity of O
6-methylguanine-
DNA methyl transferase (MGMT). In the present study, we show that sensitivity of melanoma cells to TMZ was dependent on their
p53 status and levels of MGMT. Analysis of the mechanisms underlying reduced viability showed no evidence for induction of
apoptosis even though marked levels of apoptosis was seen in TK6 lymphoma cells. Sensitivity of melanoma cells was associated with
p53-dependent G2/M cell cycle arrest and induction of senescence. To verify the role of p53, the assays were repeated in presence
of pifithrin-a, an inhibitor of p53. This resulted in increased viability of melanoma cells with wild-type p53 and reversed G2/M cell
cycle arrest. Paradoxically, apoptosis was increased in melanoma but decreased as expected in TK6 lymphoma cells. These results are
consistent with the view that TMZ is relatively ineffective against melanoma due to defective apoptotic signalling resulting from
activation of p53. The nature of the defects in apoptotic signalling remains to be explored.
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Melanoma continues to increase in incidence in many parts of the
world and remains among the top six cancers as a cause of death
and morbidity. However, there has been little progress in the
medical treatment of metastatic melanoma because of the absence
of effective systemic therapies. A variety of mechanisms that may
account for resistance of melanoma cells to chemotherapy have
been described. These include decreased drug uptake into the cells,
increased drug efflux, intracellular drug inactivation, repair of
drug-induced damage, or resistance to drug-induced apoptosis
(Pepponi et al, 2003; Plummer et al, 2005).
Alkylating agents are among the most widely used chemo-
therapeutic agents for the treatment of metastatic melanoma.
Temozolomide (TMZ), a second-generation imidazoletetrazinone
derivative, is known to have clinical activity against melanoma
(Pepponi et al, 2003; Plummer et al, 2005). By the oral route, it has
a bioavailability of almost 100% and is rapidly absorbed. At
physiological pH, TMZ hydrolyses to the cytotoxic methylating
product, 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (Middlemas
et al, 2000; Plummer et al, 2005). The cytotoxicity of TMZ is
believed to be mediated mainly through the addition of a methyl
group to the O
6 position of guanine (G) in genomic DNA (Tentori
et al, 1997; Middlemas et al, 2000; Plummer et al, 2005). The
methyl group in O
6-methylguanine can be removed by
O
6-methylguanine-DNA methyl transferase (MGMT) (Tentori
et al, 1997; Hirose et al, 2001). Unless repair occurs, O
6-
methylguanine is a cytotoxic lesion due to mispairing of G with
thymine (T) during the next cycle of DNA replication (Middlemas
et al, 2000). This triggers the DNA mismatch repair (MMR) system
that removes, but then reinserts the T during repair synthesis
(Hirose et al, 2001).
Futile cycles of MMR induced by GT mismatches have been
reported to lead to a variety of outcomes, such as G2/M cell cycle
arrest, cellular senescence, and apoptosis in TMZ-treated cells
(Hirose et al, 2001; Gunther et al, 2003). p53 is thought to play a
critical role in determining the sensitivity of cells to TMZ because
the futile DNA repair cycles induces the accumulation of p53
protein, and transcriptional targets involved in cellular processes
such as proliferation and apoptosis (Tentori et al, 1997; D’Atri
et al, 1998; Hirose et al, 2001). For example, p53 has been shown to
affect both the duration of cell cycle arrest and the fate of human
glioblastoma cells treated with TMZ (Hirose et al, 2001). Mutations
in the p53 gene are a common feature in many types of cancers,
and are frequently associated with resistance to chemotherapeutic
agents including TMZ (Tentori et al, 1998; Hussein et al, 2003).
In haematopoietic neoplasms, p53 status has been shown to be
directly correlated with sensitivity to TMZ-induced apoptosis
(Tentori et al, 1998).
To address the responses of melanoma to TMZ and to determine
the role of p53, we employed melanoma cell lines that express wild
type or mutant p53. We report in the present study that treatment
of melanoma cells with TMZ resulted in p53-dependent reduction
in cell viability, which was due to induction of G2/M cell cycle
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sarrest and cellular senescence. No significant apoptotic events
could be observed after treatment of melanoma with TMZ even
when MGMT was inhibited.
MATERIALS AND METHODS
Cell lines
Human melanoma cell lines Me4405, IgR3, Mel-FH, Mel-CV,
MM200, and SK-mel-28 were cultured as described previously
(Zhang et al, 2001). TK6 and MT1 lymphoblastic cells were kindly
provided by Dr Josef Jiricny, University of Zurich.
Antibodies and other reagents
TMZ, kindly provided by the Schering-Plough Research Institute
(NJ, USA), was prepared freshly in dimethyl sulphoxide (DMSO) at
a final concentration of 0.1%. (v/v). MGMT, O
6-benzylguanine
(BG), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), X-gal, potassium ferricyanide, potassium ferrocyanide, and
propidium iodide (PI) were purchased from Sigma-Aldrich (Castle
Hill, NSW, Australia). The rabbit polyclonal Ab against caspase-3,
the mouse MAbs against poly(ADP-Ribose) polymerase (PARP),
and p21 were purchased from Pharmingen (Marrickville, NSW,
Australia). The MAb against p53 (clone BP53-12) was purchased
from Upstate Biotechnology (Lake Placid, NY, USA). The anti-
phospho-AMPK-a (Thr172) was purchased from Cell Signaling
Technology.
Cell viability assays
These assays were performed using MTT as described previously
(Wu et al, 2005).
Apoptosis
Quantitation of apoptotic cells by measurement of sub-G1 DNA
content using the PI method or by Annexin-V staining was carried
out as described previously (Zhang et al, 2001; Gillespie et al,
2004).
PI uptake assay
The PI uptake assay was performed as described previously (Zhang
et al, 2006).
Cell cycle analysis
Sub-confluent, exponentially proliferating cells were treated with
TMZ and were harvested, counted and 1 10
6 cells were stained
with PI buffer (10mgml
 1 PI, 1% tri-sodium citrate, 0.1% Triton
X-100, 100mM NaCl). Cell cycle distribution was determined using
a FACscan flow cytometer and Cell Quest analysis software.
Mitochondrial membrane potential (DWm)
Changes in the mitochondrial membrane potential were measured
as described previously (Zhang et al, 2006).
Colony formation assays
Melanoma cells were seeded in 6-well culture plates at fixed
densities (500 cells per well) 16–24h before the addition of TMZ.
At the end of the assay (12–15 days after treatment), cells were
fixed with methanol and stained with crystal violet. Colonies with
50 or more cells were counted using phase contrast microscopy.
Western blot analysis
Western blots were performed as described previously (Zhang
et al, 1999).
Transfection of siRNA
The human melanoma cell line, IgR3, was seeded at a density of
2 10
5 cells per well in a 6-well plate 24h prior to transfection.
Cells were transfected with 100nM p21 siRNA or a non-specific
target (control) siRNA (siGENOME ON-TARGET plus SMARTpool
duplex, Dharmacon, Lafayette, CO, USA) using Lipofectamine 2000
(Invitrogen, Mount Waverley, VIC, Australia) according to the
manufacturers’ instructions. After 24h of transfection, cells were
treated with 100mM of TMZ or the control (0.1% DMSO) for 72h,
then harvested for western blots or cell-cycle distribution analysis.
SA-b-gal assay
The activity of b-galactosidase (b-gal) at a sub-optimal pH of 6.0
was measured as a biomarker of senescence as described elsewhere
(Dimri et al, 1995).
Statistical analysis
Data are expressed as mean±s.e. The statistical significance of
intergroup differences in normally distributed continuous vari-
ables was determined using Student’s t-test. P-values of less than
0.05 were considered statistically significant.
RESULTS
TMZ reduces cell viability and colony formation in
melanoma cells
To examine the antitumour potential of TMZ, we performed cell
viability analysis on a panel of melanoma cell lines exposed to
TMZ. All cell lines apart from SK-mel-28 and Mel-FH express wild-
type p53 as analysed by DNA sequencing (data not shown). Cells
were treated with TMZ (0–500mM), either alone or in combination
with BG at 10mM for 72h and then cell growth was evaluated using
Table 1 Effect of TMZ or TMZ plus BG on the proliferation of
melanoma cell lines
IC50 (lM)
c
Cell line
a
Relative expression
of MGMT
b (fold) TMZ TMZ plus BG
ME4405 2.11 36±1.9 29±2.3
SK-mel-28 16.78 4256 194±6.3
MM200 1.13 23±2.1 17±1.2
IgR3 0.99 22±2.3 16±0.9
Mel-CV 4.01 29±4.1 19±1.67
Mel-FH 14.88 4247 187±11.2
Mel-RM 12.32 4256 89±9.6
Abbreviations: TMZ¼temozolomide; BG¼benzylguanine; MGMT¼O
6-methylgua-
nine-DNA methyl transferase; MTT¼3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide; DMSO¼dimethyl sulphoxide.
aCells were incubated with graded
concentration of TMZ for 72h and then analysed for cell growth using MTT assay.
BG at 10mm was added to the cell cultures 2h before TMZ and maintained for the
entire period of the assay. Control groups were either untreated or treated with BG
or DMSO alone.
bThe intensity of the MGMT bands was quantitated with the
Bio-Rad VersaDoc image system (Bio-Rad, Regents Park, NSW, Australia). The
relative expression of MGMT was determined by dividing the densitometric value of
MGMT by that of the a-tubulin control.
cDrug concentration required to inhibit cell
growth by 50%. Each value represents the mean±s.e. of three independent
experiments performed with quadruplicate culture.
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level of MGMT was associated with sensitivity to TMZ. MM200 and
IgR3 cell lines (express wild-type p53 and low MGMT levels)
showed comparable sensitivity to TMZ, with IC50 values of 23 and
22mM, while SK-mel-28 and Mel-FH (mutant-type p53 and high
MGMT level) cell lines were resistant with IC50 values of 4256 and
4247mM, respectively. Mel-RM cell line, with wild-type p53 and
high content of MGMT, was extremely resistant to TMZ. Pre-
treatment with BG has significantly sensitised melanoma cells to
TMZ-induced growth inhibition.
Long-term effect of TMZ was studied in colony formation
assays. Figure 1A and B show that TMZ inhibited colony formation
in MM200 and IgR3 cell lines even when used at concentrations as
low as 25mM. At 100mM, a clinically relevant concentration (Brada
et al, 1999), colony formation was reduced to 22% of the control in
IgR3 and 23% in MM200 cells. In contrast, inhibition of colony
formation in SK-mel-28 and Mel-FH cells was observed only when
TMZ was used at 75mM or higher. At clinically relevant dose of
TMZ, the efficiency of colony formation was 89% of the control in
SK-mel-28 and 74% in Mel-FH.
Similarly, cells with wild type or mutant p53 pre-treated with
BG followed by treatment with TMZ for 12 days displayed lower
numbers of colonies than those treated with TMZ alone. It is
notable that even in the presence of BG, inhibition of colony
formation by TMZ appeared to be more efficient in cells with wild-
type p53 than those with mutated p53 (Figure 1C).
No evidence for apoptosis in melanoma cells treated with
TMZ
To study if the TMZ-induced reduction of cell viability of
melanoma cells was due to induction of cell death, we studied
cellular and molecular apoptotic events after treatment with TMZ
for 72h. As shown in Figure 2A and B, there was no significant
apoptotic cell death after exposure to TMZ for 72h as evidenced by
lack of sub-G1 DNA fragmentation or activation of caspase-3 and
processing of its substrate PARP. TRAIL is known to induce
apoptosis of melanoma cells and was used as a positive control in
these assays (16h exposure to TRAIL) (Zhang et al, 2001). TK6
(sensitive) and MT1 (resistant) lymphoblastoid cells were used as a
control for TMZ-induced apoptosis (D’Atri et al, 1998). Resistance
to apoptosis in melanoma cells did not appear to be due to
activation of intracellular survival signalling pathways mediated
by Akt and ERK1/2 in that apoptosis was not detected when
melanoma cells were pre-treated with inhibitors of these pathways
(data not shown).
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Figure 1 Colony formation in melanoma cell lines with wild type or mutant p53 at different concentration of temozolomide (TMZ). (A and B) MM200,
IgR3, Mel-FH, and SK-mel-28 cells were seeded overnight before the treatment with or without TMZ at indicated doses for 12 days, and the numbers of
colonies were quantitated. (A) Percentages of colony numbers relative to the negative controls. (B) Photographic images of the colonies. The data shown
are representative of three experiments. (C) Cells were pre-treatment with or without benzylguanine (BG) at 10mM for 2h followed by addition of TMZ at
100mM for 12 days. The data shown are mean±s.e. of three independent experiments.
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sMost genotoxic agents including TMZ act primarily via p53 to
induce apoptosis (Tentori et al, 1998; Bocangel et al, 2002), at least
in part, by transcriptional activation of its target genes such as Bax,
Noxa, and PUMA (Villunger et al, 2003). Figure 2C shows that
Noxa and PUMA were constitutively expressed in the MM200 and
SK-mel-28 melanoma cells and they and Bax were not upregulated
after exposure to TMZ. p53 was weakly upregulated at 24 and 48h
in the MM200 cells but strongly upregulated in both cell lines by
72h. These results contrast with studies on the TK6 lymphoblas-
toid cells in that TMZ-induced p53 and its downstream targets
Noxa and PUMA by 24h after treatment.
Uptake of PI into cells is a test for plasma membrane integrity
and indicates necrosis when observed in the absence of evidence
for apoptosis such as early plasma membrane externalisation of
phosphatidylserine and detected by Annexin V staining (Walsh
et al, 1998). Double staining with fluorescein isothiocyanate
(FITC)-conjugated Annexin-V and PI revealed uptake of PI in
16% of MM200 cells and was not significant in SK-mel-28 cells
(1.1%) after treatment with TMZ for 72h (Figure 2D). Kinetic
studies indicated that the majority of TMZ-treated MM200 cells
did not become Annexin-V positive unless they first became PI
positive (see Supplementary Figure S1).
Changes in mitochondrial membrane potential have been
documented not only in apoptotic cell death, but also in other
forms of cell death such as necrosis (Kroemer and Reed, 2000).
Using a fluorescent cationic dye 5,50,6,60-tetrachloro-1,10,3,30-tetra-
ethyl-benzamidazolocarbocyanin iodide, known as JC-1 (Nihal et al,
2005), we found that treatment with TMZ resulted in a reduction in
DCm in wild-type p53 (MM200) cells without being detected in
mutant p53 (SK-mel-28) suggesting the absence of either apoptosis
or necrosis of the latter (Supplementary Figure S2).
TMZ induces G2/M cell cycle arrest in melanoma cells that
is associated with accumulation of wild-type p53 and p21
We carried out cell cycle analysis of two cell lines with wild-type
p53 (MM200 and IgR3) and two with mutant p53 (SK-mel-28 and
Mel-FH) by DNA flow cytometric analysis. Results revealed that
cell lines with wild-type p53 began to accumulate at the G2/M
boundary 48h after treatment with TMZ (Figure 3A). This G2/M
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Figure 2 (A) Temozolomide (TMZ) does not induce apoptosis of melanoma cells. MM200 and SK-mel-28 cells were pre-treated with or without
benzylguanine (BG) (10mM) for 2h and then with TMZ at 100mM for 72h. Apoptosis was assessed by measurement of sub-G1 DNA content. TRAIL
(200ngml
 1) was used as a positive control. MT1 and TK6 were seeded in medium containing TMZ (25mM) for 48h before measurement of apoptosis. The
data shown are representative of three individual experiments. (B) TMZ does not induce caspase-3 activation. MM200 and SK-mel-28 cells were treated
with TMZ (100mM) for the indicated time periods. Processing of caspase-3 and its substrate PARP was measured by western blot analysis on whole cell
lysates. TRAIL (200ngml
 1) was used as a positive control. Western blot analysis of glyceraldehydes-3-phosphate dehydrogenase (GAPDH) level was
included to show that equivalent amounts of protein were loaded in each lane. The data shown are representative of two individual experiments. (C) TMZ
does not induce transcriptional activation of p53 target genes; Bax, Noxa, or PUMA. MM200 and SK-mel-28 cells were treated with TMZ (100mM) for the
indicated time periods and the whole cell lysates were subjected to western blot analysis. The data shown are representative of two individual experiments.
(D) TMZ-induced plasma membrane perturbation occurs earlier than externalisation of phosphatidylserine and augmented in presence of BG. MM200 and
SK-mel-28 cells pre-treated with or without BG (10mM) followed by addition of TMZ (100mM) for 72h were stained with fluorescein isothiocyanate (FITC)-
conjugated Annexin-V and PI and analysed using flow cytometry. Numbers indicated the percentage of cells in each quadrant. The data shown are
representative flow cytometry quadrant plot graphs of three individual experiments.
Temozolomide-induced growth inhibition of melanoma
NM Mhaidat et al
1228
British Journal of Cancer (2007) 97(9), 1225–1233 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sarrest was sustained for at least 10 days after exposure to TMZ
(Figure 3B) and was associated with the gradual appearance of
hyperploid (44n DNA content) cells and the gradual decrease of
cells with 2n DNA content (G1 population). In contrast, little or no
accumulation of cells at the G2/M boundary was observed in
melanoma cell lines that expressed mutant p53.
Both p53 and p21 are known to play a key role in cell cycle
regulation (D’Atri et al, 1998; Martin et al, 2005). As shown in
Figure 3C, the levels of p53 were increased approximately 20-fold
in MM200 and 8-fold in IgR3 cells 72h after exposure to TMZ.
Similarly, the levels of p21 were increased about 14-fold in MM200
and 6-fold in IgR3 at the same time point. In contrast, no
significant change was found in the levels of p21 before and after
treatment with TMZ in Mel-FH that expresses mutant p53. There
was no detectable p21 expression in SK-mel-28 even in the
presence of TMZ. Accumulation of p53 and p21 in MM200 and
IgR3 cells persisted for at least 10 days after treatment (data not
shown).
We investigated the role of p21 in induction of G2/M arrest
by siRNA knockdown of p21 as described under Materials
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Figure 3 Temozolomide (TMZ) induces G2/M cell cycle arrest in association with accumulation of p53- and p21. (A) Melanoma cells treated with TMZ
(100mM) for the indicated time periods were subjected to cell cycle analysis in flow cytometry. The data shown are percentages of the cells in G2/M phase
(mean±s.e. of three individual experiments). (B) Representative flow cytometry histograms obtained from cells treated with TMZ (100mM) for 10 days. (C)
TMZ upregulates p53 and p21. Whole cell lysates were subjected to western blot analysis. The data shown are representative of two individual experiments.
(D) IgR3 cells were transfected with control siRNA or p21 siRNA and whole cell lysates were subjected to western blot analysis of p21 expression.
Representative flow cytometry histograms of cell cycle distribution are shown for transfected cells which were treated with TMZ (100mM) for 72h or
treated with the control (DMSO). These results are representative of three independent experiments performed in duplicate.
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sand Methods. As shown in Figure 3D, there was almost
complete inhibition of G2/M arrest when p21 was knocked down
by siRNA.
Verification of the role of p53
To verify the role of p53 in TMZ-induced anti-proliferative
activity, we studied the effect of TMZ on cell proliferation and
cell cycle distribution in presence and absence of the p53 inhibitor
pifithrin-a [PFT-a, 2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-
1-(4-methylphenyl)ethanone] also called QB102. PFT-a has been
reported to inhibit p53 function temporally in vitro (Komarov
et al, 1999) by a reversible inhibition of p53-dependent
transactivation of p53-responsive genes and to protect cells against
a variety of genotoxic agents through inhibition of p53-mediated
apoptosis (Culmsee et al, 2001). Figure 4A shows that after
exposure to TMZ for 72h, the expression of both p53 and p21 in
MM200 cells was increased but were significantly inhibited when
the PFT-a was used at 10mM (cisplatin at 10ı `gml
 1 for the past 24h
was used as a positive control). p53 inhibitor partially protected
MM200 against TMZ-induced growth inhibition when TMZ was
used at 25 or 100mM (Figure 4B). The inhibitor however did not
affect TMZ-induced growth inhibition of SK-mel-28 cells. PFT-a
could not protect MM200 cells when TMZ was used at a higher
dose (250mM) indicating that TMZ may induce p53-independent
cell growth inhibition when used at high doses. As shown in
Figure 4C, the levels of apoptosis induced by TMZ in MM200 and
IgR3 cells were increased in the presence of PFT-a. In contrast,
PFT-a inhibited apoptosis in the TK6 lymphoma cells. Moreover,
Figure 4D shows that pre-treatment with PFT-a decreased the
proportion of cells arrested at G2/M indicating that G2/M arrest
was p53 dependent.
We asked whether cells treated with both TMZ and BG were
inhibitable by PFT-a as BG might increase sensitivity to TMZ.
MM200 cells were treated with BG at 10mM for 2h and both
TMZ (at 100mM) and PFT-a (at 10mM) added for 72h. G2/M arrest
was decreased from 48% in the absence of PFT-a to 16% in the
presence of PFT, similar to the results shown in Figure 4D.
Similarly, addition of BG did not increase or decrease the degree of
apoptosis induced at 72h in MM200 treated with TMZ plus PFT-a
(data not shown).
TMZ induces cellular senescence in melanoma cell lines
with wild type or mutant p53
Several cytotoxic agents including TMZ were reported to induce
cellular senescence (Hirose et al, 2001; Schwarze et al, 2005). We
examined if TMZ induces cellular senescence in melanoma cells
treated with TMZ by measuring SA b-gal activity using immuno-
histochemistry. As shown in Figure 5A, SA b-gal positive cells
could be detected as early as 48h after treatment with TMZ in both
p53-wild-type MM200 and IgR3, and p53-mutant SK-mel-28 and
Mel-FH cells. At 5 days after exposure to TMZ, 65% of MM200 and
69% of IgR3 cells were positive, whereas only 35% of SK-Mel-28
and 42% of Mel-FH cells appeared to be positive for SA b-gal
activity. Most of the SA b-gal positive cells also exhibited
morphological characteristics of senescence with increased size
and flattened shape (Figure 5B). The pre-treatment with BG
increased the number of cells positive for SA b-gal irrespective of
their p53 status (Figure 5C).
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Figure 4 (A) Pifithrin-a induces dose-dependent inhibition of p53 transcriptional activity. MM200 cells were pre-treated with the indicated doses of
pifithrin-a before the addition of temozolomide (TMZ) (100mM) for 72h or CDDP (10mgml
 1) for 24h as a positive control. Whole cell lysates were
subjected to the western blot analysis for p53 and p21 expression. The data shown are representative of two individual experiments. (B) Pifithrin-a protects
melanoma cells against TMZ-induced growth inhibition. MM200 and SK-mel-28 cells were pre-treated with or without pifithrin-a (10mM) for 2h before the
addition of TMZ at the indicated doses for another 72h. Cell viability was assessed using MTT assay. The data shown represent percentages of viable cells
relative to the negative controls (mean ± s.e. of three individual experiments). (C) Inhibition of p53 sensitises melanoma cells to TMZ-induced apoptosis.
Melanoma and lymphoblastoma cells were treated with or without pifithrin-a for 3h before adding TMZ for the indicated time points before measurement
of apoptosis by the propidium iodide method. The data shown are representative of three individual experiments. (D) Pifithrin-a inhibits TMZ-induced G2/
M cell cycle arrest. MM200 and IgR3 cells were pre-treated with pifithrin-a TMZ (10mM) for 3h before adding TMZ (100mM) for 72h. Cells were subjected
to cell cycle analysis in flow cytometry. The data shown are percentages of the cells in G2/M phase (mean±s.e. of three individual experiments).
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(AMPK) is increased in cells undergoing senescence and its over-
activation promoted senescence in primary human fibroblasts (Wang
et al,2 0 0 3 ;X i a n get al, 2004). The level of phosphorylated AMPK was
increased in MM200 cells but not SK-mel-28 after 48h of treatment
with TMZ and significantly accumulated after 72h (Figure 5D).
DISCUSSION
In the present study, sensitivity of melanoma cells to TMZ in
assays of cell viability was shown to be dependent on the p53 status
of the cells and their levels of MGMT. Melanoma cells with wild-
type p53 had much reduced viability in the presence of TMZ
compared to melanoma cells with mutated p53. Inhibition of
MGMT with O
6-benzylguanine resulted in further decrease in cell
viability and this correlated with western blot analysis of MGMT
levels in the melanoma cells.
Studies in animal models with alkylating agents have suggested
that reduced viability would be the result of p53-mediated
induction of proapoptotic BH3-only proteins leading to apoptosis
via the mitochondrial pathway (Villunger et al, 2003). In the
absence of apoptosis, cell death may result from necrosis, perhaps
due to activation of PARP and consumption of ATP (Zong et al,
2004). This mechanism was shown to account for induction of
necrosis by cisplatin in melanoma cells that were resistant to
apoptosis (Zhang et al, 2006). In the present studies, there was no
evidence that TMZ induced apoptosis in melanoma cells lines even
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Figure 5 Benzylguanine (BG) enhanced temozolomide (TMZ)-induced cellular senescence. (A, B and C) Melanoma cells were seeded onto glass
coverslips 16–24h before the pre-treatment with or without BG (10mM) and then addition of TMZ (100mM) for the indicated time periods. Cells were
stained with senescence-associated b-Gal stain solution, and were analysed using a microscope. The data shown are percentages of the b-Gal positive cells
(mean±s.e. of three individual experiments) (A and C) and representative micrographs of three individual experiments (B). Bar¼30mm. (D) Melanoma
cells were treated with TMZ (100mM) for the indicated time points. Whole cell lysates were subjected to the western blots for phosphorylated AMP-
activated protein kinase (AMPK) expression. Data shown are representative of two individual experiments.
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apoptosis in TK6 lymphoma cells at much lower concentration
(25mM) than that used against the melanoma cells. Moreover,
failure of apoptosis was not due to insensitivity of the cells to
apoptosis as they were sensitive in varying degrees to TRAIL and
cisplatin-induced apoptosis and in previous studies to docetaxel
(Mhaidat et al, 2007).
Treatment with TMZ did not induce upregulation of Noxa or
PUMA, which act as ‘sensor’ proteins in induction of apoptosis by
DNA-damaging agents in a p53-dependent manner (Moll and
Zaika, 2001). These proteins were however upregulated in the TK6
lymphoma cells. In addition, inhibition of survival pathways
mediated by Akt and ERK1/2, which are known to protect
melanoma from apoptosis induced by varying stimuli (Hagemann
and Blank, 2001; Wu et al, 2005), did not potentiate TMZ-induced
apoptosis. There was also relatively little evidence of cell necrosis
(o10% of cells) based on PI uptake, lack of DNA fragmen-
tation, delayed externalisation of phosphatidylserine, and absence
of processing of PARP. These changes were mainly noted 48h
after treatment with TMZ consistent with the finding that the
effect of TMZ does not take place until the second cell cycle
O
6-methyl G:T mismatches occur and MMR is triggered
(D’Atri et al, 1998).
The main effect of TMZ on melanoma cells appeared to be p53-
dependent cell cycle arrest in the G2/M phase. This was associated
with upregulation of p21 in the cells with wild-type p53 but not in
cells with mutated p53 where p21 levels were unchanged or
undetectable after exposure to TMZ. These changes were
associated with cellular senescence as shown by detection of SA-
b-gal activity, morphological changes of senescent cells, and
increased levels of AMP-activated protein kinase. Senescence
appeared to be associated with p53 status in that the percentage of
senescent cells was much higher in the cell lines with wild-type p53
than those with mutant p53 (for example, 65 and 35% in MM200
and SK-mel-28, respectively). The mechanism by which TMZ
induces senescence in glioblastoma cells is thought to be by
upregulation of p21 and inhibition of CDK2 (Hirose et al, 2001). In
addition, p53-independent mechanisms may be involved but these
are unclear. Busulfan was reported to induce senescence via the
MAP kinase pathway (Probin et al, 2006). Similarly, in diterpine
ester-treated melanoma cells, the senescence mechanism appeared
to involve activation of the Ras–Raf–MEK–ERK pathway (Cozzi
et al, 2006). Inhibition of MEK in the present study did not
potentiate killing of the melanoma cells, which argues against this
mechanism. It is unclear why p21 was upregulated whereas other
p53 target genes such as PUMA and Noxa were not. Nevertheless, it
is well known that there may be selective expression of p53 target
genes due to cofactors such as the apoptosis stimulating proteins
of p53 (Sullivan and Lu, 2007).
It is also unclear why inhibition of p53 with PFT-a resulted in an
increase in apoptosis of human melanoma cells particularly as
apoptosis of TK6 lymphoma cells was inhibited. Increased levels of
apoptosis were also reported by others in glioma cells treated with
PFT-a. It was speculated that this may be due to failure of the cells
to undergo DNA repair during cell cycle arrest (Hirose et al, 2001;
Xu et al, 2005). A similar interpretation could be placed on the
current results. The actual mechanism of apoptosis is unknown
except that it is presumably independent of p53-mediated path-
ways. We have reported elsewhere (Zhang et al, 2006) that
melanoma may express smaller molecular weight isotypes of p53,
and it is possible that these may act as a dominant negative
regulator of some but not all p53 target genes. Studies on this
aspect are in progress but if proven, it suggests that the resistance
of melanoma to TMZ may in large part be due to abnormalities in
p53-mediated regulation of its target genes.
In summary, the present studies confirm that the levels of
MGMT play a role in resistance of melanoma to TMZ but also
indicate that apoptotic cell death pathways are not activated by
TMZ. Instead, reduced cell viability appeared to result from G2/M
arrest and induction of senescence. Necrosis played a minor role in
the effects of TMZ on melanoma. Resistance to apoptosis appears
at least in part due to a p53-dependent mechanism perhaps
resulting from cell cycle arrest and repair of DNA. These results
provide new insights into the mechanism of action of TMZ and
new approaches in its use against melanoma perhaps with agents
which reactivate functions of p53 (Bossi and Sacchi, 2007).
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